CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Strongbridge Biopharma plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Strongbridge Biopharma plc
900 Northbrook Dr Ste 200
Phone: (610) 254-9200p:610 254-9200 TREVOSE, PA  19053-8433  United States Fax: (215) 355-7389f:215 355-7389
This company was Merged or Acquired on 10/5/2021.
This company ceased filing statements with the SEC on 10/15/2021.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202112/31/2020YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Financial Officer Richard S.Kollender 51 3/3/2021 3/1/2015
Chief Executive Officer John H.Johnson 63 7/2/2020 3/1/2015
Chief Medical Officer Frederic J.Cohen 55 11/1/2016 11/1/2016
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Cortendo AB
SBBP
Strongbridge Dublin Limited
Strongbridge U.S. Inc.

General Information
Number of Employees: 72 (As of 12/31/2020)
Outstanding Shares: 67,828,952 (As of 8/2/2021)
Shareholders: 13
Stock Exchange: NASD
Federal Tax Id: 981130690
Fax Number: (215) 355-7389


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 2, 2024